Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

NCT01764633 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

27564

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

BIOLOGICAL: Evolocumab
DRUG: Placebo

Sponsor

Amgen